Trial Search Results

Erwinia Asparaginase After Allergy to PEG-Asparaginase in Treating Young Patients With Acute Lymphoblastic Leukemia

This clinical trial is studying the side effects of Erwinia asparaginase and what happens to the drug in the body in treating young patients with acute lymphoblastic leukemia who are allergic to PEG-asparaginase. Drugs used in chemotherapy, such as Erwinia asparaginase, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Children's Oncology Group

Collaborator: National Cancer Institute (NCI)

Stanford Investigator(s):

Intervention(s):

  • Drug: Asparaginase
  • Other: Laboratory Biomarker Analysis
  • Other: Pharmacological Study

Phase:

N/A

Eligibility


Inclusion Criteria:

   - Diagnosis of acute lymphoblastic leukemia

   - Concurrently enrolled on a frontline Children's Oncology Group treatment trial (i.e.,
   COG-AALL0232 or COG-AALL0531, COG-AALL0331, or COG-AALL0434) at a participating
   institution

      - Must have 1 or more courses of asparaginase remaining to be administered on the
      treatment protocol

   - Must have had a grade ? 2 hypersensitivity reaction to PEG-asparaginase

   - No history of pancreatitis ? grade 2

   - No prior Erwinia asparaginase

Ages Eligible for Study

1 Year - 30 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Peds Hem/Onc CRAs
650-723-5535
Not Recruiting